Last reviewed · How we verify

Quick response: Amoxicillin for 3 days — Competitive Intelligence Brief

Quick response: Amoxicillin for 3 days (Quick response: Amoxicillin for 3 days) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic (aminopenicillin). Area: Infectious Disease.

marketed Beta-lactam antibiotic (aminopenicillin) Penicillin-binding proteins (PBPs) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Quick response: Amoxicillin for 3 days (Quick response: Amoxicillin for 3 days) — University Hospital, Montpellier. Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins and blocking peptidoglycan cross-linking.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Quick response: Amoxicillin for 3 days TARGET Quick response: Amoxicillin for 3 days University Hospital, Montpellier marketed Beta-lactam antibiotic (aminopenicillin) Penicillin-binding proteins (PBPs)
Amoxicillin Short Amoxicillin Short Universita degli Studi di Genova marketed Beta-lactam antibiotic (aminopenicillin) Penicillin-binding proteins (PBPs)
I.V ampicillin 2 gram x4/d for 2 days I.V ampicillin 2 gram x4/d for 2 days Western Galilee Hospital-Nahariya marketed Beta-lactam antibiotic (aminopenicillin) Penicillin-binding proteins (PBPs); bacterial peptidoglycan
P.O moxypen 500 mgx3/d for 5 days P.O moxypen 500 mgx3/d for 5 days Western Galilee Hospital-Nahariya marketed Beta-lactam antibiotic (aminopenicillin) Penicillin-binding proteins (PBPs)
Oral amoxicillin Oral amoxicillin Boston Medical Center marketed Beta-lactam antibiotic (aminopenicillin) Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
Amoxicillin Capsules Amoxicillin Capsules The Third Xiangya Hospital of Central South University marketed Beta-lactam antibiotic (aminopenicillin) Penicillin-binding proteins (PBPs); bacterial cell wall peptidoglycan
amoxicillin 1gr amoxicillin 1gr Rabin Medical Center marketed Beta-lactam antibiotic (aminopenicillin) Penicillin-binding proteins (PBPs)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic (aminopenicillin) class)

  1. University Hospital, Montpellier · 2 drugs in this class
  2. Western Galilee Hospital-Nahariya · 2 drugs in this class
  3. Medical College of Wisconsin · 1 drug in this class
  4. Norwegian University of Science and Technology · 1 drug in this class
  5. Boston Medical Center · 1 drug in this class
  6. The Third Xiangya Hospital of Central South University · 1 drug in this class
  7. Universita degli Studi di Genova · 1 drug in this class
  8. Rabin Medical Center · 1 drug in this class
  9. Far Eastern Memorial Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Quick response: Amoxicillin for 3 days — Competitive Intelligence Brief. https://druglandscape.com/ci/quick-response-amoxicillin-for-3-days. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: